Clinical Trials Logo

AL Amyloidosis clinical trials

View clinical trials related to AL Amyloidosis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04115956 Terminated - AL Amyloidosis Clinical Trials

A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

Start date: August 6, 2020
Phase: Phase 1
Study type: Interventional

This is a phase 1/2 open label study of melphalan flufenamide (melflufen) in combination with dexamethasone for participants with Al amyloidosis following at least one prior line of therapy. Melflufen will be administered on Day 1 of each 28-day cycle in combination with dexamethasone on days 1 and 2. In both phases, treatment of each individual participant will continue for up to 8 cycles or until any stopping events occur. Approximately 46 participants will be enrolled. The study was intended to be a Phase 1/2 trial but was early terminated and never moved forward to Phase 2.

NCT ID: NCT03154047 Terminated - AL Amyloidosis Clinical Trials

Study in Subjects With Light Chain (AL) Amyloidosis

Start date: June 14, 2017
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who have completed Study NEOD001-201.

NCT ID: NCT03000660 Terminated - AL Amyloidosis Clinical Trials

Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

Start date: January 2017
Phase: Phase 1
Study type: Interventional

This is a study to determine the safety, tolerability and maximum tolerated dose of Venetoclax (ABT-199) and dexamethasone in relapsed or refractory amyloid light chain (AL) amyloidosis patients.

NCT ID: NCT02613182 Terminated - AL Amyloidosis Clinical Trials

Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

OLE
Start date: February 2016
Phase: Phase 2
Study type: Interventional

The rationale for this study is to provide additional treatment with NEOD001 for subjects who complete Study NEOD001-001, and to continue to evaluate long term safety and tolerability. All subjects in the current NEOD001 trials are being dosed at 24 mg/kg, which will be continued in this study.

NCT ID: NCT02489500 Terminated - AL Amyloidosis Clinical Trials

Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib

VelRand
Start date: June 2015
Phase: Phase 3
Study type: Interventional

Standard treatment for AL Amyloidosis is high-dose melphalan and stem cell transplant. This study will compare the safety and effectiveness of standard treatment with high-dose melphalan and stem cell transplant, compared with investigational bortezomib when used in combination with standard treatment with high-dose melphalan and stem cell transplant for AL amyloidosis.